DIRS.INFO The most relevant business & tech news

☆ Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds
▼ + stars: | 2024-05-24 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +8 min

Diabetes is a key risk factor for kidney disease, which is one of the leading causes of death in the United States and worldwide; about 1 in 3 people with diabetes also has chronic kidney disease, according to the US Centers for Disease Control and Prevention. But new research shows that weekly injections of semaglutide cut the risk of severe outcomes from diabetic kidney disease by about 24%. The new study found even broader related benefits of semaglutide treatment among people with diabetic kidney disease. “Kidney disease attributed to diabetes, or diabetic kidney disease, is one of the most common and deadly complications of diabetes. Yet, unfortunately, there’s very low awareness around it,” said Dr. Katherine Tuttle, chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology.

Persons: ”, Vlado Perkovic, “ Semaglutide, Martin Holst Lange, Katherine Tuttle, ” It’s, Tuttle, semaglutide, It’s, Dr, Sanjay Gupta, White, ” Tuttle Organizations: CNN, Diabetes, US Centers for Disease Control, New England, of Medicine, European Renal Association Congress, University of New, University of New South Wales Sydney, Novo Nordisk, American Society of Nephrology, Providence Inland Northwest Health, Health Sciences, University of Washington, CNN Health Locations: United States, University of New South, Danish, American

☆ This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
▼ + stars: | 2024-05-23 | by ( Michelle Fox | ) www.cnbc.com time to read: +7 min

RBC Capital Markets sees a $25 billion market opportunity for the space. The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet. Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon AstraZeneca's one-year performanceAstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon Bristol-Myers Squibb's one-year performance

Persons: It's, Gregory Renza, Renza, Oppenheimer, Jeff Jones, Piper Sandler, Edward Tenthoff, Eli Lilly, Dan Lyons, Janus Henderson, Myers Squibb, William Blair, Matt Phipps, Jefferies, Andrew Tsai, They've, Janus Henderson's Lyons, Jones, Piper Sandler's Tenthoff, Myers Organizations: pharma, RBC Capital Markets, TRT, Novartis, Mariana Oncology, Janus, Janus Henderson Investors, Bristol, RayzeBio, Karuna Therapeutics, AstraZeneca, Fusion Pharmaceuticals, GlobalData's Pharma Intelligence, Pluvicto Locations: Mariana, Bristol

☆ Chemical toxin exposure in the womb linked to greater health risks for children ages 6 to 11
▼ + stars: | 2024-05-23 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +11 min

CNN —Chemical toxins are everywhere — in our water, food, air and soil. Children born to European mothers exposed to four families of chemicals that disrupt the body’s endocrine (hormone) system had elevated levels of metabolic syndrome at ages 6 to 11. Metabolic syndrome can include obesity, elevated blood pressure, and abnormally high cholesterol and insulin resistance, which is a precursor to type 2 diabetes. Metabolic syndrome is typically associated with adult cardiovascular disease, type 2 diabetes and stroke, but the growing epidemic of childhood obesity has seen symptoms appearing in kids at younger and younger ages. Having metabolic syndrome as a child is highly predictive of chronic disease as an adult, experts say.

Persons: Nuria Güil, ”, Oumrait, Vicente Mustieles, Mariana Fernández, Carmen Messerlian, Messerlian, phthalates, “, Jane Houlihan, ” Houlihan, Houlihan, PFAS, EWG Organizations: CNN, Icahn School of Medicine, JAMA, Biomedical Research, University of Granada, Harvard, of Public Health, International Council for Chemical Associations, American Chemistry Council, EPA, Food, Food and Drug Administration, FDA, NSF, National Sanitation Foundation Locations: Mount Sinai, New York City, Spain, Messerlian, Chan, Boston, United States

☆ Healthy diets with only 10% ultraprocessed foods may raise risk of cognitive decline, stroke
▼ + stars: | 2024-05-22 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +5 min

All three diets are plant-based, focused on consuming more fruits and vegetables, whole grains, beans and seeds while limiting sugar, red meat and ultraprocessed foods. Eating more ultraprocessed foods such as hot dogs is linked to a higher risk of stroke and cognitive decline, according to a new study. What is it about ultraprocessed foods that may allow them to sabotage efforts to follow a healthy diet? Growing dangers of ultraprocessed foodsStudies on the dangers of eating ultraprocessed foods are piling up. That 10% increase was considered “baseline,” and adding even more ultraprocessed foods might increase the risk, experts say.

Persons: ”, Andrew Freeman, ’ ”, Dr, W, Taylor Kimberly, Kimberly, Peipei Gao, Zhendong Mei, Mei, Gao, Harvard T.H, ’ ” Freeman Organizations: CNN, Jewish Health, Whites, Blacks, Massachusetts General Hospital, Brigham, Women’s Hospital, Harvard, of Public Health Locations: Denver, Massachusetts, Boston, Chan

☆ These are JPMorgan’s highest conviction stock picks over the next 12 months
▼ + stars: | 2024-05-22 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

Specifically, analyst Chris Schott called Eli Lilly one of his highest conviction opinions. Analyst Harlan Sur noted that one of his top picks includes semiconductor manufacturer Broadcom , which has rallied 25% in 2024. In the report, the bank also highlighted data centers as an area that investors should watch. As demand grows for data centers, beneficiaries could include stocks such as Vertiv , up an eye-watering 106% in 2024, which is one of analyst Steve Tusa's highest conviction picks in the electrical equipment industry. Other stocks JPMorgan listed in the report include Delta Airlines and Carvana .

Persons: Chris Schott, Eli Lilly, Harlan Sur, Steve Tusa's, Rajat Gupta, — CNBC's Michael Bloom Organizations: JPMorgan, Dow Jones, Major Pharma, Broadcom, Delta Airlines

☆ Nestlé is releasing a lineup of frozen food for people on Ozempic and other GLP-1 drugs
▼ + stars: | 2024-05-21 | by ( Jordan Valinsky | ) edition.cnn.com time to read: +4 min

New York CNN —Nestlé, the maker of frozen food brands like Stouffer’s and DiGiorno, is slimming down with a new line of meals for people taking GLP-1 drugs, such as Ozempic, for weight loss. However, a recent study on Wagovy significantly reduced heart risk in addition to helping with weight loss. An example of Vital Pursuit food. It also made a $100 million-plus deal to buy Sequence, a telehealth business that offers virtual prescriptions to patients for these weight loss drugs where appropriate. Food companies, like Nestlé, are also bracing for GLP-1 consumers to buy fewer sugary snacks and drinks.

Persons: New York CNN — Nestlé, It’s, Morgan, Steve Presley, Neil Saunders, Nestlé, it’s “, Saunders, ”, “ Nestlé, Sesame, WeightWatchers, ” Saunders, CNN’s Nathaniel Meyersohn Organizations: New, New York CNN, North, GlobalData, Lean, CNN, Companies, Costco, Equinox Locations: New York

☆ Many people using GLP-1s for weight loss stop treatment too soon, research shows, and results are not one-size-fits-all
▼ + stars: | 2024-05-21 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +8 min

Professional organizations have set this as a guideline for when to reassess whether a treatment is providing clinically meaningful weight loss. People who met with their providers less frequently – and those living in underserved regions with broader health inequities – were more likely to discontinue GLP-1 treatment sooner. But using GLP-1 treatments are still an investment in many ways. These injected medications, called GLP-1 agonists, are in high demand because they have proved to be so effective for weight loss. And experts warn that the GLP-1 treatment process can be different for everyone.

Persons: ”, Disha, Wegovy, Jody Dushay, Beth, There’s, Razia Hashmi, ” Hashmi, it’s, “, Dr, Sanjay Gupta, ” Narang, ” Dushay Organizations: CNN, Endeavor Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Shield, Dandelion Health, CNN Health, “ Locations: Chicago, –, GLP

☆ JPMorgan says there's a new GLP-1 drug player and its shares can rally 80%
▼ + stars: | 2024-05-21 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Structure Therapeutics is an overlooked player in the GLP-1 market, and could one day boast a competitive product and go up against Eli Lilly and the like, according to JPMorgan. Analyst Hardik Parikh initiated research coverage on the clinical stage drug developer with an overweight rating and $65 price target, implying 82% potential upside. According to Parikh, Structure's current $1.7 billion market value undervalues 1290's peak sales opportunity to generate more than $1 billion by 2035. Parikh estimated that Structure will launch 1290 for Type 2 diabetes, or T2D, after 2029. Additionally, Parikh thinks Structure could be an attractive partnership opportunity for larger drug companies looking to get involved in the market for obesity and Type 2 diabetes treatments.

Persons: Eli Lilly, Hardik Parikh, Parikh, Eli Lilly's Organizations: Therapeutics, JPMorgan, pharma, Novo Nordisk, Parikh Locations: T2D

☆ This overlooked obesity-drug stock has 80% upside, JPMorgan says
▼ + stars: | 2024-05-21 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

Structure Therapeutics is an overlooked stock that could surge on the GLP-1 weight loss craze. "Meaningful upside from even a small piece of unprecedentedly large GLP-1 market," JPMorgan said. AdvertisementStructure Therapeutics is developing the drug candidate dubbed "1290," which is a "pure-play option" for the GLP-1 weight loss market, according to JPMorgan. JPMorgan said early results suggest the drug candidate offers "on par" weight loss results for patients with "no major concerns on safety." Advertisement"We think GPCR's market share in the oral market can approach 5% over time in an unprecedentedly large market.

Persons: —, Eli Lilly, Eli, orforglipron, Eli Lilly's Organizations: Therapeutics, JPMorgan, Service, Novo Nordisk, GLPP, Nasdaq

☆ People using popular drugs for weight loss, diabetes are more likely to be diagnosed with stomach paralysis, studies confirm
▼ + stars: | 2024-05-20 | by ( Brenda Goodman | ) edition.cnn.com time to read: +9 min

Injected medications called GLP-1 agonists are in high demand because they have proved to be so effective for weight loss. The difference, which was statistically significant, amounted to a 52% increased risk of being diagnosed with stomach paralysis while on a GLP-1 medication. Compared with those who were not taking a GLP-1 medication, those who did were about 66% more likely to be diagnosed with gastroparesis. This study found that 0.53% of patients on GLP-1 medications were diagnosed with stomach paralysis, or about 1 case of gastroparesis for every 200 people taking the drugs. People taking GLP-1 medications were also more likely to have nausea and vomiting or gastroesophageal reflux disease (GERD) and to be prescribed a proton pump inhibitor.

Persons: gastroparesis, GERD, ”, Prateek Sharma, Sharma, ” Sharma, Michael Camilleri, “, Camilleri, It’s, who’d, Dr, Sanjay Gupta, it’s Organizations: CNN, Drugmaker, Nordisk, University Hospitals, Diabetes, University of Kansas, University of Kansas School of Medicine, American Society, Mayo Clinic, CNN Health Locations: Washington, Cleveland, GLP, Mayo

☆ I'm an American mom living in France. I've never seen a screen out during meal time and French kids are always well-dressed.
▼ + stars: | 2024-05-20 | by ( Erica Jackson Curran | ) www.businessinsider.com time to read: +7 min

And yet, when I'm in Mom Mode with my 7-year-old son, Oliver, I just can't hide the fact that I'm American. This kind of helicopter behavior is fairly common among American parents — but less so in France. French kids are always impeccably dressedIt may sound like French kids are running wild, but that's not the case — and their wardrobes are evidence of that. I've rarely seen French kids with screens (or sodas) at a restaurant. AdvertisementWe've learned that French kids usually snack only once per day, during "gouter" which is around 4:30 p.m., when they get out of school.

Persons: Oliver, I've, —, that's, He's, he's, I'm, they're, iPads I've, Coke, We've Organizations: Service, Adidas Locations: Bordeaux, France, American, French

☆ Opinion | Obesity, Weight-Loss Drugs and Ultraprocessed Foods
▼ + stars: | 2024-05-19 | by ( ) www.nytimes.com time to read: +1 min

I also like the idea of treating obesity as a medical condition rather than a moral failure or sign of weakness. Individuals can decide about Ozempic and similar drugs taking into consideration the known benefits and risks as well as the unknowns. Not discussed in Mr. Hari’s excellent article is the need for the entire population, including those who are not overweight, to eat a well-balanced diet that largely omits ultraprocessed foods and is generous with fruits and vegetables. There are many proven benefits, including reducing the risks of heart disease, cancer and Type 2 diabetes. Even if one does not lose an ounce, moving a diet in this direction will be beneficial.

Persons: Johann Hari, Hari, Jonathan Freudman San Organizations: Mr, Calif Locations: Jonathan Freudman San Rafael

☆ Your kids’ ultraprocessed food consumption may put them at higher risk, study shows
▼ + stars: | 2024-05-17 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +5 min

CNN —The ultraprocessed foods your kids eat now may be putting them a greater risk for cardiometabolic problems – like heart attack, stroke and diabetes – in adulthood, a new study suggests. Researchers divided the data from the children into three groups based on the amount of ultraprocessed food they ate. “This particular topic, ultraprocessed food consumptions and risk, is a very important topic in kids,” he said. The ultraprocessed foods kids eat now may have lasting impacts, a new study suggests. In places where fresh food might be harder to obtain, ultraprocessed foods are more accessible and inexpensive, Freeman said.

Persons: ”, Stuart Berger, Andrew Freeman, Berger, Robert H, Lurie, Brendan Smialowski, ” Freeman, …, Freeman, there’s Organizations: CNN, American Academy of Pediatrics, Food and Agriculture Organization, United Nations, Jewish Health, Ann, Lurie Children’s Hospital, Getty, BMI Locations: Spain, Denver, Chicago, AFP

☆ Step aside, Ozempic — Zyn is the new (delusional) weight-loss quick fix
▼ + stars: | 2024-05-17 | by ( Mia De Graaf | Hilary Brueck | ) www.businessinsider.com time to read: +8 min

Now, Zyn users are buzzing about another purported side effect: Some claim that their habit has triggered weight loss. Andrea Hernández, author of consumer trend newsletter Snaxshot, pointed out this craze this week, sharing a collection of social media posts about Zyn and weight loss. "I've used Zyn nicotine pouches occasionally over the past few years but have started to use them regularly because they help me focus and curb my hunger," a Reddit user wrote in r/intermittentfasting. While nicotine pouches circumvent the health effects of cigarettes that are caused by tobacco, they still do a number on your body. She worries that "we don't fully understand how nicotine works to regulate appetite in people, specifically with obesity."

Persons: —, Tucker Carlson, Carlson, Andrea Hernández, I've, Carolyn Bramante, Bramante, vapes, Slim, Apple AirPods, Philip Morris, Forget, I'm, Elon Musk, Charles Barkley, Hernández, Michael M, Beverly Tchang, Tchang, Iuliia Burmistrova Organizations: Service, Business, University of Minnesota, FDA, Lucky, Samsung, Getty, Weill, Philip Morris International, Swedish Locations: New York

☆ Eli Lilly falls on a rival's obesity study — plus, we're removing 3 stocks from our watchlist
▼ + stars: | 2024-05-16 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Eli Lilly dips: Shares of Eli Lilly are sitting out the rally on news that Swiss pharmaceutical firm Roche 's experimental obesity drug demonstrated promise in a Phase 1 study. "Doug McMillon, the CEO of Walmart, made the point repeatedly that the company's success this quarter came from lower prices," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Roche, It's, inflect, We're, Doug McMillon, Estee Lauder, Jim, Jim Cramer's Organizations: CNBC, Viking Therapeutics, Club, Deere, Walgreens Boots, Walmart, Costco, Materials, Jim Cramer's Charitable Locations: Swiss, Amgen, China

☆ Roche says weight loss drug shows promising results in early trial
▼ + stars: | 2024-05-16 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Roche on Thursday said its experimental weight loss drug showed promising results in an early-stage trial, boosting the company's bid to compete in the booming market for those treatments. But its weekly weight loss injection, called CT-388, is still years away from entering the market. The treatment works by mimicking the effect of two gut hormones — GLP-1 and GIP — to suppress a person's appetite, just like Eli Lilly's popular weight loss drug Zepbound and diabetes injection Mounjaro. Scientists have hypothesized that targeting those two hormones could have a meaningful effect on weight loss and blood sugar levels with fewer side effects than drugs that only target GLP-1, such as Novo Nordisk's weight loss treatment Wegovy. Eli Lilly's Zepbound delivered up to 22% weight loss after 72 weeks, while Novo Nordisk's Wegovy has led to 15% weight loss after 68 weeks.

Persons: Roche, Eli Lilly, Roche's, —, Eli Lilly's, Eli Lilly's Zepbound, Novo Nordisk's Wegovy Organizations: Roche, AG, Carmot Therapeutics, Novo Nordisk, Novo Nordisk's Locations: Basel, Switzerland, Swiss, Roche's, Novo

☆ These diets may reduce cancer, heart disease and early death, according to a 20-year review
▼ + stars: | 2024-05-15 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +8 min

CNN —Eating a vegan, vegetarian or lacto-ovo vegetarian diet significantly reduces the overall risk of developing cancer, heart disease and dying early from cardiovascular disease, according to a new “umbrella” analysis of more than 20 years of research. “Plants have more fiber (animal foods have zero), less saturated fat and zero cholesterol (all animal foods have cholesterol),” Gardner said in an email. However, vegetarian diets limiting but not completely excluding certain types of meat and fish, such as pesco- or pollo-vegetarian diets, were excluded, he said. “Strictly vegan diets can be deficient in vitamin B12,” Gardner said. “Iron is another nutrient that is harder to get from a fully vegan diet,” Gardner added.

Persons: ”, Dr, Angelo Capodici, Federica, Guaraldi, David Katz, ” Katz, Christopher Gardner, Gardner, ” Gardner, “, Davide Gori, ” Gori, It’s, Wesley Soares Ferracini Organizations: CNN, Scuola Superiore, IRCCS Institute of Neurological Sciences, True Health Initiative, Stanford Prevention Research Center, University of Bologna, Mayo Clinic, B12 Locations: Pisa, Italy, Bologna, Palo Alto , California

☆ I'm ashamed of taking weight-loss drugs. It took me years to love my body, and now I worry what other people will think.
▼ + stars: | 2024-05-15 | by ( Krista Atkinson | ) www.businessinsider.com time to read: +6 min

If you'd told me 10 years ago I'd feel ashamed of losing weight, I wouldn't have believed you. I've been on a roller coaster of body shame and acceptance since I was 12, which, at times, led to bouts of disordered eating. My primary doctor suggested I try a medical weight loss program, which involves seeing a nutritionist and weight loss doctor monthly, as well as prescription weight loss drugs. I've been scared because of the hurtful commentary and speculation I see online about others losing weight by taking medication. However, I am conscience-stricken for taking weight loss medicine when all I am trying to do is improve my health.

Persons: you'd, I've, I'd, I'm

☆ More young people are being diagnosed with cancer. 3 lifestyle changes could reduce your risk, according to a cancer dietitian.
▼ + stars: | 2024-05-14 | by ( Serafina Kenny | ) www.businessinsider.com time to read: +4 min

Read previewA dietitian specializing in cancer prevention told Business Insider that simple lifestyle changes can be powerful when it comes to reducing the risk of developing cancer. The rates of younger adults being diagnosed with cancer have been rising since the '90s, according to the American Cancer Society, with colorectal, breast, and stomach cancers a particular concern. But certain lifestyle choices can help to prevent cancer, Tejal Parekh, a registered and licensed dietitian who specializes in helping mesothelioma patients reduce cancer symptoms through diet at Asbestos.com, told Business Insider. Research suggests that diets high in salt are linked to an increased risk of stomach cancer. Exercise regularly and maintain a healthy weightBeing physically active for at least 30 minutes daily can help prevent cancer, Parekh said.

Persons: —, Tejal Parekh, dietitian, Parekh, Parekh it's Organizations: Service, American Cancer Society, US Centers for Disease Control, Business, International Agency for Research, Cancer, Research, CDC, Health Organization, National Cancer Institute

☆ Celebrities can't lose weight without people speculating they're on Ozempic. Here's who's addressed rumors — as Kelly Clarkson denies she's taken it.
▼ + stars: | 2024-05-14 | by ( Rachel Hosie | Amber Middleton | ) www.businessinsider.com time to read: +1 min

Ozempic and Wegovy are both forms of semaglutide, a drug originally developed for diabetes. OEL SAGET/AFP via Getty ImagesOzempic and Wegovy are the brand names used by the drug manufacturer, Novo Nordisk. Tirzepatide, marketed as Mounjaro for diabetes, is a similar "game-changer" drug, and has been approved for weight loss under the name Zepbound. Ozempic has become the byword for semaglutide and similar drugs that cause weight loss (known as GLP-1s), regardless of which brand a person is taking or why. They work by suppressing appetite, but side effects such as muscle loss, nausea, and diarrhea have been reported, and it's common to regain the weight after stopping treatment.

Persons: SAGET, Ozempic Organizations: Getty, Novo Nordisk, Semaglutide, FDA Locations: AFP

☆ People on Novo Nordisk's Wegovy maintain weight loss for up to four years, study says
▼ + stars: | 2024-05-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Patients taking Novo Nordisk 's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis published Tuesday from the longest clinical trial to date on the treatment. The highly popular drug also reduced the risk of heart disease regardless of a patient's weight, a second analysis on the same trial found. Neither Novo Nordisk or Eli Lilly , which has its own weight loss drug, have been able to produce enough supply to meet the insatiable demand for their treatments. The SELECT trial, which included more than 17,000 patients from over 40 countries, tested Wegovy for its cardiovascular benefits.

Persons: Wegovy, Eli Lilly Organizations: Novo Nordisk, European, Obesity, Insurance, Nordisk's, U.S . Food, Drug Administration Locations: London, Britain, Venice, Italy, U.S

☆ What the results of Wegovy’s longest clinical trial yet show about weight loss, side effects and heart protection
▼ + stars: | 2024-05-13 | by ( Meg Tirrell | ) edition.cnn.com time to read: +10 min

CNN —New analyses of the longest clinical trial yet of the weight-loss drug Wegovy are shedding light on how quickly it helps people lose weight, how long they sustain that weight loss and how safe the medicine is over four years of use. A previous clinical trial showed even greater average weight loss for Wegovy: about 15% on average over 68 weeks, compared with 2.4% for people who got a placebo. It was sustained for up to four yearsThe results showed that the 10% average weight loss for people using Wegovy was sustained for up to 208 weeks, or four years. Patients stayed on the medicine while they sustained the weight loss. Almost 23% of people on Wegovy lost at least 15% of their body weight, compared with 1.7% on a placebo.

Persons: Wegovy, –, ”, Harlan Krumholz, Dr, Donna Ryan, Eli Lilly, wasn’t, they’d, Daniel Drucker, it’s, John Deanfield, Krumholz, Drucker, GLP, Sanjay Gupta Organizations: CNN, Yale University, Yale New Haven Hospital, drugmaker, Nordisk, Novo Nordisk, European, Obesity, Nature, Pennington Biomedical Research, University of Toronto, University College London, CNN Health Locations: Baton Rouge , Louisiana, Novo

☆ Just how bad are ultraprocessed foods? Here are 5 things to know
▼ + stars: | 2024-05-13 | by ( Andrea Kane | ) edition.cnn.com time to read: +8 min

NOVA separates foods into four groups, starting with natural and minimally processed foods in the first category to ultraprocessed foods, which use industrial formulations and manufacturing techniques, in the fourth. Here are five things to know about ultraprocessed foods:Ultraprocessed foods are linked to bad health outcomesEating a lot of ultraprocessed foods isn’t healthy. We have one.”Ultraprocessed foods cause weight gainThat one randomized, controlled clinical trial showed that ultraprocessed foods actually caused people to gain weight. So, all those factors probably play a huge role in … the foods that we choose to eat in the real world.”Not all ultraprocessed foods are badSome ultraprocessed foods can provide important nutrients, such as whole wheat bread and yogurt. “Which goes to show that not all ultraprocessed foods necessarily drive this effect.”Hall’s team is conducting a new study to tease out which ultraprocessed foods are harmful and which are neutral, or even healthy.

Persons: Marion Nestle, Meg Tirrell, Paulette Goddard, Nestle, ”, ” Nestle, Kevin Hall, ” Hall, Tirrell, shouldn’t, you’re, we’re Organizations: CNN, University of São Paulo, NOVA, Nestle, New York University, National Institute of Diabetes, National Institutes of Health Clinical, ”, National Health, US Department of Agriculture, US Food and Drug Administration Locations: Brazil, Bethesda , Maryland

☆ A precision medicine doctor shares 5 diet tips that could help you live longer
▼ + stars: | 2024-05-13 | by ( Serafina Kenny | ) www.businessinsider.com time to read: +5 min

Dr. Florence Comite is a precision medicine doctor who specializes in healthy aging. She shared five diet tips she shares with patients to help them live longer. AdvertisementA precision medicine doctor shared with Business Insider six diet tips she gives her patients to help them live healthily for as long as possible. A separate study from 2023 found that people who ate diets rich in whole grains, nuts, and fruit lived around 10 years longer than those who consumed more red meat, processed foods, and sugary drinks. 10'000 Hours/ GettyDespite its name, the Mediterranean diet is more of an eating plan that is low in processed foods and red meat.

Persons: —, Florence Comite, jittery, Dietitians Organizations: Florence Comite, Service, Business, Allied Market Research, Comite Center, Precision Medicine & Health, Nutrition Board, National Academies of Sciences Engineering, Medicine, Comite Locations: Florence, York

☆ How Ozempic Is Changing Diabetes Treatment
▼ + stars: | 2024-05-13 | by ( Dani Blum | ) www.nytimes.com time to read: +1 min

Day in and day out, she carefully calibrated the doses needed to keep her Type 2 diabetes in check. “Every meal, and every morning and every night — it controls your life,” she said. In late 2021, she started on the diabetes drug Ozempic. She still uses a continuous glucose monitor to track her blood sugar, meticulously watching for slumps and spikes — but even as she took less insulin, she said, Ozempic has helped keep her glucose levels more under control. Millions of Americans rely on some form of insulin, a lifesaving drug that has long been a mainstay of diabetes treatment.

Persons: Betsy Chadwell, ”, Ozempic, Chadwell, “, Scott Hagan Organizations: University of Washington

Search resuls for: "Obesity"

25 mentions found